Quantcast
Last updated on April 19, 2014 at 8:29 EDT

Latest Actavis Stories

2014-04-17 16:27:20

DUBLIN, April 17, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that it has entered into agreements with Akorn, Inc. and Hi-Tech Pharmacal Co. Inc. to purchase four currently marketed products and one product under development for cash consideration. The closing of the purchase agreements are contingent upon the consummation of Akorn's acquisition of Hi-Tech. Financial terms of the agreements were not disclosed. The...

2014-04-17 16:27:16

DUBLIN and NEW YORK, April 17, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Forest Laboratories, Inc. (NYSE: FRX) today announced that they have each received a request for additional information from the Federal Trade Commission ("FTC") in connection with Actavis' pending acquisition of Forest. The information request was issued under notification requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"). The effect of the second...

2014-04-17 08:27:47

BOSTON, April 17, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on April 29, 2014, to discuss financial results of the first quarter ended March 31, 2014. Frank Condella, President and Chief Executive Officer, and Jonathan Lloyd Jones, Vice President and Chief Financial Officer of Columbia Laboratories, will host the call as follows: Date: Tuesday, April 29, 2014 Time: 8:30 am EDT...

2014-04-15 08:29:42

DUBLIN, April 15, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Mylan Inc. and Famy Care Ltd. to settle all outstanding patent litigation related to Mylan's generic version of Generess(®) FE (norethindrone, ethinyl estradiol and ferrous fumarate chewable tablets). Under the terms of the agreement, Actavis will grant Mylan a license to market its generic version of Generess(®) FE under its pending Abbreviated New Drug...

2014-04-03 12:30:06

LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013 The market for injectable generics has been through a period of consolidation over the last few years as the leading companies have increased their presence through acquisition. The major players include Hospira, Sandoz (Novartis), Hikma Pharmaceuticals, Fresenius Kabi and Teva Pharmaceutical...

2014-04-03 08:31:17

Fuld & Company White Paper Released CAMBRIDGE, Mass., April 3, 2014 /PRNewswire/ -- A Fuld & Company white paper which chronicles the history of Forest Laboratories and its market position that led to its acquisition by Actavis was released today. The white paper http://bit.ly/1lAw5Lo provides details including: -- Forest's actions in recent years that made it acquisition bait -- How one of the most successful US pharmaceutical companies of the last decade finds itself...

2014-04-02 20:22:35

- Centralized Headquarters to help drive Company's Geographic Expansion, Growth in Emerging Markets throughout Southeast Asia - SINGAPORE, April 2, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced the official opening of its new regional office in Singapore that will serve as the headquarters for the Company's Asia Pacific and Africa (APACA) region. In addition, Actavis announced that its subsidiary operating in...

2014-04-01 08:29:34

- Establishes Leading Position in Fast-Growing Thai Pharmaceutical Market - DUBLIN, April 1, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company today announced that it has acquired Silom Medical Company, a privately held generic pharmaceutical company focused on developing and marketing therapies in Thailand, for approximately $100 million in cash. The acquisition of Silom Medical immediately elevates Actavis into a top-five position...

2014-04-01 08:28:47

DUBLIN, April 1, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has successfully completed the divestiture of its generics commercial operations in seven markets in Western Europe to Aurobindo Pharma Limited (BSE: 524804). The agreement to divest the commercial operations was announced in January 2014. http://photos.prnewswire.com/prnvar/20130124/NY47381LOGO Aurobindo acquired Actavis' pharmaceutical commercial infrastructure in France, Italy, Spain,...

2014-03-28 16:22:54

DUBLIN, March 28, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the United States Court of Appeals for the Federal Circuit has reversed a lower court ruling that Actavis' generic version of Shire's Lialda(®) (mesalamine extended-release tablets) infringes United States Patent No. 6,773,720 (the '720 Patent). The Appeals Court found that the U.S. District Court for the Southern District of Florida did not correctly construe the claims of the '720 Patent, and...